Clinical news

Lana Dykes is the Editor of Rheumatology Network. She is an experienced editor and technical writer with a demonstrated history of working in the banking and publishing industries. She enjoys cooking, yoga, and drawing. 

Videos

Previous attempts to make associations between JIA and prenatal maternal infection is difficult due to the rarity of JIA diagnosis and recall bias. 

Is There a Link Between Maternal Infection and Juvenile Idiopathic Arthritis? 

Ingrid Torjesen is a UK-based freelance health journalist with more than 30 years of experience in health and medical communications. She works for numerous publications including Rheumatology Network, the BMJ and the Economist’s Intelligence Unit. Before her freelance career, her staff jobs included news editor of both Pulse and GP (the two leading UK weekly titles for primary care doctors), and opinion and features editor of the Health Service Journal (the UK’s leading health policy title). She also spent a few years working in Australia, including on Australian Doctor.

Articles

Many people now use activity trackers to assess their activity levels, but what role can these devices play in managing rheumatoid arthritis patients? Test your knowledge with this quiz.

Rheumatoid Arthritis Quiz: Activity Trackers and RA

“The differential contribution of IL-6 and IL-17 pathways to the pathogenesis of psoriatic arthritis is not fully understood,” investigators stated.

Upadacitinib Significantly Decreases Biomarker BD2 in Patients with PsA

Take a few minutes to check out Rheumatology Network's top expert interviews from Q2 2022. 

Rheumatology Network's Top 5: Q2 Expert Interviews

The approval and implementation of new drugs can vastly improve quality of life and reduce signs and symptoms of disease burden in patients with rheumatic and dermatologic diseases. 

FDA Decisions to Watch in Rheumatology in Second Half of 2022

The Committee for Medicinal Products for Human Use (CHMP) recommends approving upadacitinib 15 mg, once daily, for the treatment of active non-radiographic axial spondyloarthritis in adults patients with inflammation and inadequate response to NSAIDs. 

Upadacitinib Receives Positive CHMP Opinion for Treatment of Non-Radiographic Axial Spondyloarthritis 

Take a few minutes to discover Rheumatology Network's most-viewed EULAR 2022 coverage. 

Rheumatology Network: Best of EULAR 2022

The approvals were based on results from the JUNIPERA trial, which showed secukinumab reduced the risk of flare and disease activity when compared with placebo over 2 years in pediatric patients with ERA and JPsA.

Secukinumab Receives Expanded Approvals in EU for Pediatric Arthritic Conditions 

"The challenges of an existing rheumatologist workforce shortage, changing workforce demographics, and physician burnout have been compounded by the COVID-19 pandemic."

Shortage of Canadian Rheumatologists Linked to Increase in Burnout

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending June 25, 2022.

Rheumatology